ARADIGM CORPORATION Inactive Instrument
Aradigm Corporation Share Price Nasdaq
Equities
US0385054004
Biotechnology & Medical Research
| Sales 2016 | 195K 16.26M | Sales 2017 | 14.46M 1.21B | Capitalization | 97.3M 8.11B |
|---|---|---|---|---|---|
| Net income 2016 | -32M -2.67B | Net income 2017 | -10M -834M | EV / Sales 2016 | 73.3 x |
| Net cash position 2016 | 9.37M 781M | Net Debt 2017 | 7.91M 660M | EV / Sales 2017 | 7.27 x |
| P/E ratio 2016 |
-0.72
x | P/E ratio 2017 |
-9.3
x | Employees | - |
| Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 60.28% |
More Fundamentals
* Assessed data
More news
More press releases
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
